A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis

British Journal of Dermatology

Volumn 147, Issue 4, 2002, Pages 748-753

  Tzaneva, S ^a   Seeber, A ^b   Honigsmann H ^a   Tanew, A ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b Donauspital/SMZ Ost ^*  (Austria)

Author keywords

Combination therapy; Psoralen plus ultraviolet A; Psoriasis; Tacalcitol; Tazarotene

Indexed keywords

BERGAPTEN; GERALEN; METHOXSALEN; PSORALEN; TACALCITOL; TAZAROTENE;

ADULT; ARTICLE; BURNING SENSATION; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HYPERTRICHOSIS; IRRITANT DERMATITIS; MALE; NAUSEA; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; RADIATION DOSE; RADIATION RESPONSE; RELAPSE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINIC ACIDS; PSORIASIS; PUVA THERAPY; RADIATION DOSAGE; SEVERITY OF ILLNESS INDEX;

EID: 0036406114     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2002.04896.x     Document Type: Article

References (16)

1. Momtaz TK, Fitzpatrick TB, Modifications of PUVA. Dermatol Clin 1995; 4: 867-73.
2. Morison WL, Baughman RD, Day RM et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134: 595-8.
3. Peters DC, Balfour JA. Tacalcitol. Drugs 1997; 54: 265-71.
4. van de Kerkhof PCM, Werfel T, Haustein UF et al. Tacalcitol ointment in the treatment of psoriasis vulgaris: A multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996; 135: 758-65.
5. Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: A randomized double blind placebo study in severe psoriasis. Eur J Dermatol 1993; 3: 351-4.
6. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol 1994; 130: 79-82.
7. Kokelj F, Plozzer C. Reduction of UV-A radiation induced by calcipotriol in the treatment of vulgar psoriasis with oral psoralen plus UV-A. Arch Dermatol 1997; 133: 668-9.
8. Grundmann-Kollmann M, Behrens S, Krähn G et al. Treatment of psoriasis with calcipotriene plus psoralen-UV-A-bath therapy. Arch Dermatol 1999; 135: 861-2.
9. Kokelj F, Plozzer C, Doria TA, Trevisan G. Association of tacalcitol and PUVA in the treatment of psoriasis. G Ital Dermatol Venereol 2000; 135: 243-6.
10. Chandraratna RAS. Tazarotene - First of a new generation of receptor-selective retinoids. Br J Dermatol 1996; 135: 18-25.
11. Duvic M. Tazarotene: A review of its pharmacological profile and potential for clinical use in psoriasis. Exp Opin Invest Drugs 1997; 6: 1537-51.
12. Koo JY. Tazarotene in combination with phototherapy. J Am Acad Dermatol 1998; 39: S144-8.
13. Behrens S, Grundmann-Kollmann M, Peter R-U, Kerscher M. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. Br J Dermatol 1999; 141: 177 (Letter).
14. 3 derivative tacalcitol increases the responsiveness to 311-nm ultraviolet B: Results of a controlled, right/left study. Br J Dermatol 2001; 144: 628-9.
15. Lowe NJ. Optimizing therapy: Tazarotene in combination with phototherapy. Br J Dermatol 1999; 140 (Suppl. 54): 8-11.
16. Veien NK, Bjerke JR, Rossmann-Ringdahl I et al. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997; 137: 581-6.